Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (6520)	6/22/1998 2:05:00 PM
From: opalapril	Read Replies (1) \| Respond to of 17367

I share your concern. Right now, for instance, I am wondering "Does the Whole World Except Me Know the Status of the Orphan Drug Application?" Also, as you know, I think Xoma has a lot more information than they are disclosing about the ongoing P-3 clinical results. Mr. Castello indicated as much when speaking about death rates. That is one reason why I personally worry about lack of fund and insider buying interest. I suppose one must resign oneself to the reality that the small, loyal investor is always the last to know in this industry, but it doesn't for a moment ease the frustration. Speaking of which, remember these words? "I really can't put my finger on why this stock continues to frustrate me... ." I actually tracked down the author of those prescient words and asked him what he thought about Xoma today. Essentially, he replied that Xoma soured him on biotechs and he no longer pays attention. He has, it seems, moved on and up while the rest of have been left behind to ponder his pitiless permanent post.

To: aknahow who wrote (6520)	6/22/1998 6:43:00 PM
From: Tharos	Read Replies (4) \| Respond to of 17367

Notes from Dr. Falk's presentation in England. I too, am disappointed and think I will stop asking Xoma first and post instead: THE BPI TRIALS Saul Faust MRCP MRC Clinical Training Fellow (Previously BPI Fellow), Department of Paediatrics, Imperial School of Medicine at St. Mary's. What is rBPI? rBPI21 is a recombinant amino terminal fragment of a basic 55kD protein found in the azurophilic granules of human neutrophils. rBPI21 is bactericidal against several strains of E.coli and has been shown to increase survival and reduce morbidity in rodent and rabbit models of gram negative infections. The Phase 2 trial Reported in The Lancet in November 1997, 26 children enrolled in an open label clinical trial we treated with encouraging results using historical controls. The Phase 3 trial in children The phase 3 trial is an international multicentre trial taking place at centres in the UK and USA. An independent data review board monitor the study at set intervals to ensure the trial enrols sufficient patients to reach statistical significance. Review of the first 100 patients did not highlight any safety concerns, and currently the final number of patients estimated to be required is 300. Entry to the trial All children aged 3 months-18 years are eligible for entry to the trial if they suffer from no existing medical conditions and have a modified Glasgow Meningococcal Prognostic Score (GMSPS) of 8 or above. Entry is stratified into a high (12-15) and low (8-11) GMSPS score. Parenteral antibiotics must have been administered less than 8 hours from the start of the rBPI21 infusion. Logistical issues Most patients are enrolled on retrieval at the referring hospital. For ethical and legal purposes, clinical responsibility passes to the retrieval team at arrival at the referring hospital. Informed consent is a prerequisite of entry to the trial. Current numbers admitted to trial (23rd April 1998) UK 143 (73%) of which St. Mary's: 76 (39%) Guy's: 15 (7.5%) Liverpool: 15 (7.5%) Other Centres: 37 (19%) USA Centres: 52 (27%) TOTAL 195 (100%) Centres participating in trial and principal investigators: UK - 9 centres St. Mary's London (Levin), Guy's (Murdoch), Great Ormond St. (Klein), Alder Hey Liverpool (Thomson), Newcastle (Hoare), Leicester (Nichani), Nottingham (Thomas), Stoke-on-Trent (Alexander), Sheffield (Finn). USA - 16 centres Colorado (Durmowicz), Wisconsin (Gedeit), San Diego (Bradley), Cook's (Shelton), Oregon (Goldstein), Dallas (Giroir), St. Joseph's (Sastry), Seattle (Martin), Oakland (Loeffler), Portland (Quint), Tulsa (Barton), Arkansas (Jacobs), Texas (Kaplan), University Community (Orlowski), Hosp for Sick Children (Shemie), Wisconsin (Zimmerman). The adult trial of rBPI21 for severe meningococcaemia A trial in adults has started at the Hammersmith Hospital using Ealing Hospital as a satellite site.